EPO and type 2 diabetes mellitus: In 2011, Abe et al. found a significant positive correlation between EPO dose and homeostatic model assessment of insulin resistance (HOMA-IR) in patients with T2D, indicating a positive relationship between serum EPO and serum insulin in these patients [24].